CalAmp Corp. (NASDAQ:CAMP) will release its operating results for its fiscal 2015 first quarter after the market close on Tuesday, July 1, 2014. In addition, the Company will host a conference call at 4:30 p.m. Eastern (1:30 p.m. Pacific) on July 1, 2014 to discuss its financial results.
Wall Street anticipates that the Wireless Technology company will earn $0.18 per share for the quarter, which is $0.02 more than last year's profit of $0.16 per share. iStock expects CAMP to top Wall Street's consensus number, the iEstimate is $0.19.
Sales, like earnings, are expected to edge higher, increasing 7.9% year-over-year (YoY). CalAmp's consensus revenue estimate for Q1 is $57.89 million; more than last year's $53.75 million.
[Related -CalAmp (CAMP) To Supply Mobile Data Network For City Ff Buffalo Emergency Services]
Top 5 Rising Stocks To Own Right Now: Digital Ally Inc.(DGLY)
Digital Ally, Inc. engages in the production and sale of digital video imaging, audio/video recording, storage, and other products for use in law enforcement and security applications. Its digital audio/video recording and storage product line comprises an in-car digital audio/video system that is integrated into a rear view mirror; an all-weather mobile digital audio/video system designed for motorcycle, ATV, and boat uses; a miniature body-worn digital audio/video camera; a hand-held speed detection system based on light detection and ranging (LIDAR); a hand-held thermal imaging camera used for improved night vision; and a digital audio/video system, which is integrated into a law-enforcement style flashlight. The company?s products make self-contained video and audio recordings onto flash memory cards that are incorporated in the body of the digital video rear view mirror, officer-worn video, and audio system and flashlight. Digital Ally, Inc. sells its products to law enforcement agencies and other security organizations, as well as for consumer and commercial applications through direct sales and third-party distributors. The company is based in Overland Park, Kansas.
Advisors' Opinion:- [By Jayson Derrick]
Digital Ally (NASDAQ: DGLY) said that a police department in Tennessee placed an order for the company's wearable cameras, in-car systems, motorcycle video systems and VuLink connectivity devices. Shares gained 8.79 percent, closing at $12.50.
- [By James E. Brumley]
There's no denying Tesla Motors Inc. (NASDAQ:TSLA) has been one of year's top investment stories, with shares running up from less than $40 to more than $194 in just a few short months. But, as one might imagine, that 385% runup from TSLA creates something of a disconnect between the company and its share price. Time to head for the exit. Instead, a better use of that now-considerably-greater capital is a position in Digital Ally, Inc. (NASDAQ:DGLY) ... a stock that's also had a pretty good 2014, but has suffered more than a small setback since mid-September. Specifically, DGLY has pulled back from a peak price of $17.47 to a low of $9.88 as of Friday. But, it looks like that correction may have already come to an end.
10 Best Tech Stocks To Watch For 2014: Genomic Health Inc (GHDX)
Genomic Health, Inc. (Genomic Health), incorporated in August 2000, is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score, for invasive breast cancer and colon cancer and a DCIS Score for DCIS. Its Oncotype DX breast cancer test analyzes the expression levels of 21 genes and Oncotype DX colon cancer test analyzes the expression levels of 12 genes. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.
Oncotype DX Platform
The Company�� Oncotype DX platform uses its RT-PCR approach to improve cancer treatment decisions. Its diagnostic approach correlates gene expression to clinical outcomes and provides an individualized analysis of each patient's tumor. The Company has built a diagnostic infrastructure that allows it to move from research into development through to processing actual patient samples in its clinical reference laboratory. The Company offers Oncotype DX tests as clinical laboratory services. Its technology allows the Company to analyze tumor tissue samples in its clinical reference laboratory and provide physicians with genomic information specific to the patient'! s tumor. It analyzes tissues that are handled, processed and stored under routine clinical pathology laboratory practices.
Oncotype DX Breast Cancer Test
To develop its Oncotype DX breast cancer test, the Company evaluated 250 genes in three independent clinical studies, which identified a 21-gene panel whose composite gene expression profile can be represented by a breast cancer Recurrence Score. The Company conducted studies of its Oncotype DX breast cancer test with clinical samples from postmenopausal women with invasive breast cancer who were treated with aromatase inhibitors. In March 2010, the Journal of Clinical Oncology published results from a European study using its test to analyze tumor samples from over 1,200 patients in the ATAC (Arimedix, Tamoxifen, Alone or in Combination) trial, which established the use of aromatase inhibitors for adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. The study demonstrated that, along with other standard measures, such as tumor size, its Oncotype DX breast cancer test contributes independently to provide a more complete picture of prognosis for N- and N+ patients treated with aromatase inhibitors.
In December 2011, the Company presented positive results from the ECOG E5194 DCIS clinical validation study at SABCS. The study met its primary endpoint by demonstrating that a pre-specified Oncotype DX DCIS Score can predict the risk of local recurrence, defined as either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast. In December 2011, the Company made Oncotype DX available for patients with ductal carcinoma in situ (DCIS), of the breast, a pre-invasive form of breast cancer. The launch of Oncotype DX for DCIS patients was based on positive results presented from a clinical validation study of Oncotype DX breast cancer test in patients with DCIS, conducted by the Eastern Cooperative Oncology Group (ECOG), a clinical trials cooperative! group su! pported by the National Cancer Institute.
Oncotype DX Colon Cancer Test
The Company developed its gene panel by identifying 761 cancer-related genes through review of existing research literature and computer analysis of genomic databases. The 761 candidate genes were also examined to determine whether they would be useful beyond other key variables including tumor stage, tumor grade, lymph nodes examined and MMR/MSI. It selected a final set of 12 genes, which were then independently evaluated in a validation study of over 1,400 stage II colon cancer patients from the Quick and Simple and Reliable (QUASAR), randomized study of adjuvant chemotherapy in the United Kingdom. This international, multi-center randomized trial examined the recurrence risk and the benefit associated with 5-fluorouracil/leucovorin, or 5FU/LV, adjuvant chemotherapy. Gene expression was quantified by RT-PCR from manually microdissected FPE primary colon cancer tissue, and recurrence-free interval, disease-free survival and overall survival were analyzed. In January 2012, the Company presented positive results of the first clinical decision making study of the Oncotype DX colon cancer test that shows that Recurrence Score result has a significant impact on treatment recommendations for stage II colon cancer patients.
The Company competes with General Electric Company, Hologic, Inc., Novartis AG, Myriad Genetics, Inc., Qiagen N.V., Response Genetics, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Roche Holding, Ltd, Siemens AG and Johnson & Johnson.
Advisors' Opinion:- [By John Udovich]
Large and small cap cancer stocks Gilead Sciences, Inc (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Veracyte (NASDAQ: VCYT), Genomic Health, Inc (NASDAQ: GHDX), Cell Therapeutics Inc (NASDAQ: CTIC) and MetaStat Inc (OTCMKTS: MTST) have all been producing a steady stream of news lately for biotech investors looking for a way to cash in on the growth in development of�cancer treatments. Just consider the following news:
- [By Jon C. Ogg]
Genomic Health Inc. (NASDAQ: GHDX) was downgraded to Underperform from an already cautious Neutral and the price target was cut to $33 from $36 by Bank of America�Merrill Lynch.
- [By Sean Williams]
What: Shares of Genomic Health (NASDAQ: GHDX ) , a provider of genome-based clinical diagnostic tests, popped as much as 10% following the release of its first-quarter results.
- [By Keith Speights]
Genetic testing stands out as one current example of how scientific advances can help reduce medical costs. Genomic Health (NASDAQ: GHDX ) makes genetic diagnostic tests for�breast, colon, and prostate cancer. Half of the patients diagnosed with prostate cancer each year actually have a very low risk of the cancer progressing. However, 90% of these low-risk patients still undergo surgery or radiation -- at a cost of tens of thousands of dollars per patient. Genomic Health's genetic test helps identify which patients really need more extensive treatment and holds the potential to reduce overall costs.
10 Best Tech Stocks To Watch For 2014: LDK Solar Co. Ltd.(LDK)
LDK Solar Co., Ltd., together with its subsidiaries, engages in the design, development, manufacture, and marketing of photovoltaic (PV) products; and development of power plant projects. It offers solar-grade and semiconductor-grade polysilicon; and multicrystalline and monocrystalline solar wafers to the manufacturers of solar cells and solar modules. The company also provides wafer processing services to monocrystalline and multicrystalline solar cell and module manufacturers; and sells silicon materials, such as ingots and polysilicon scraps. In addition, it engages in the production and sale of solar cells and modules to developers, distributors, and system integrators; and design and development of solar power projects in Europe, the United States, and China, as well as provides engineering, procurement, and construction services. LDK Solar Co., Ltd. operates in Europe, the Asia Pacific, and North America. The company was founded in 2005 and is based in Xinyu City, t he People?s Republic of China.
Advisors' Opinion:- [By Aaron Levitt]
Both Suntech and Chaori Solar have already filed, while LDK (LDK) is in the process of doing so and delisting from the NYSE.
All of this negative activity doesn�� inspire a whole lot of confidence in Chinese solar stocks. For investors, the best course of action could be to bail on the sector completely or at least move out of individual names and into a broad play like the TAN or Market Vectors Solar Energy ETF (KWT).
- [By Travis Hoium]
What: Solar stocks are shooting higher again today as the strong run in 2013 continues. LDK Solar (NYSE: LDK ) , Canadian Solar (NASDAQ: CSIQ ) , Yingli Green Energy (NYSE: YGE ) , Hanwha SolarOne (NASDAQ: HSOL ) , and JinkoSolar (NYSE: JKS ) led the way, gaining between 10% and 22% today.
10 Best Tech Stocks To Watch For 2014: Sonus Networks Inc.(SONS)
Sonus Networks, Inc. provides voice and multimedia infrastructure solutions. The company offers session border control (SBC), voice over Internet protocol (VoIP), and access and VoIP media gateway solutions that allow the delivery of voice and multimedia sessions over IP networks. Its products include GSX9000 Open Services Switch that enables voice traffic to be transported over packet networks; GSX4000 Open Services Switch; NBS9000 Network Border Switch that permits service providers to transform their time division multiplexing networks to IP; PSX Policy & Routing Server, which translates business policies into actual call control, routing, and service selection decisions; NBS5200 Network Border Switch that provides SBC functionality; and ASX Call Feature Server that provides local area calling and regulatory features for residential and enterprise markets. The company also offers Network Analytics Suite of performance management products, including NetScore network perf ormance analysis tool, NetAssure voice quality monitoring tool, and NetEng network audit and visualization engine that are used for the collection, monitoring, reporting, and notification of performance metrics. In addition, it provides professional consulting and services to support its IP communication solutions; and program management, network deployment design, softswitch and subscriber database design, network verification and audit, custom application and adaptor development, OSS and API integration, migration and upgrade, and managed services. The company serves long-distance and local exchange carriers, Internet service providers, wireless operators, cable operators, financial institutions, retailers, state and local governments, and multinational corporations. It sells its products primarily through a direct sales force in the United States, Europe, the Asia-Pacific, and the Middle East. Sonus Networks, Inc. was founded in 1997 and is headquartered in Westford, Mass achusetts.
Advisors' Opinion:- [By Lee Jackson]
Sonus Networks Inc. (NASDAQ: SONS) was recently named to the 2013 InformationWeek 500 list of top technology innovators across the country. In July the company authorized a repurchase program to buy back up to $100 million of their stock. Lazard has a Buy rating on the stock and a $4.50 price target. The consensus target is at $4.30, and the stock closed yesterday at $3.41.
- [By Ben Fox Rubin]
Sonus Networks Inc.(SONS) agreed to buy Performance Technologies Inc.(PTIX), a supplier of network communications products, for $3.75 a share, a 26% premium of Thursday’s close, or $42 million. The companies said the deal was worth $30 million, net of Performance Technologies’ cash and excluding acquisition costs. Performance Technologies shares jumped 24% to $3.70 premarket, just under the offer price.
- [By Evan Niu, CFA]
What: Shares of Sonus Networks (NASDAQ: SONS ) have popped today by upwards of 17% after the company reported first-quarter earnings.
So what: First quarter sales totaled $63.3 million, which turned into a non-GAAP net loss of $0.02 per share. Investors were expecting just $61.1 million up top and an adjusted loss of $0.03 per share, meaning the figures were a beat relative to consensus estimates. Session border controller, or SBC, revenue was up 77% to $30 million.
10 Best Tech Stocks To Watch For 2014: Orbotech Ltd.(ORBK)
Orbotech Ltd. engages in designing, developing, manufacturing, marketing, and servicing yield-enhancing and production solutions for specialized applications in the supply chain of the electronics industry. The company?s products include automated optical inspection (AOI), automated optical repair, laser direct imaging, digital legend printing, laser drilling, laser plotters, computer-aided manufacturing, and engineering solutions for printed circuit boards (PCBs) and other electronics component manufacturing; and AOI, test, repair, and process monitoring systems for flat panel display (FPD) manufacturing. It also develops and markets character recognition solutions and services primarily to banks, financial institutions, and other payment processing institutions for use in check and healthcare payment processing. In addition, the company is involved in the research and development of products for the deposition of anti-reflective coating on crystalline silicon photovolta ic wafers for solar energy panels. It primarily serves manufacturer of PCB, FPD, liquid crystal displays, and other electronic components worldwide. The company was formerly known as Optrotech Ltd. and changed its name to Orbotech Ltd. as a result of its merger with Orbot Systems Ltd. in October 1992. Orbotech Ltd. was founded in 1981 and is headquartered in Yavne, Israel.
Advisors' Opinion:- [By John Emerson]
AOI companies had little in the way of competition since they held a specialty niche and their systems were protected by patents. Years of R&D would be required to unseat them by way of technological superiority; therefore it made more sense for a larger company to assimilate them should they wish to enter the AOI sector. That said, CAMT was much smaller than its archrival Orbitech (ORBK) in the PCB AOI sector; thus their key to long term growth lied in their penetration into the rapidly expanding semiconductor AOI sector. In that area, their main completion was August Semiconductor.
10 Best Tech Stocks To Watch For 2014: Intersil Corporation(ISIL)
Intersil Corporation designs, develops, manufactures, and markets analog and mixed-signal integrated circuits for applications in the industrial, computing, consumer, and communications electronics markets. The company?s industrial products include operational amplifiers, bridge drivers, isolated and non-isolated power management products, switches and multiplexers, video decoders, and other standard analog and power management products used in medical imaging, energy management, automotive, military, instrumentation, security surveillance, and factory automation markets. Its computing products comprise desktop, server, notebook, and network attached storage power management products, including core power devices and other power management products for peripheral devices, as well as lithium ion battery chargers. The company?s consumer products consist of handheld, display, gaming, light sensor, and class-D audio amplifier products for use in smartphones, LCD televisions, tablet computers, electronic game systems, set top boxes, MP3 players, GPS systems, AV receivers, and home audio systems. Its communication products include line drivers, isolated and non-isolated power management, radiation-hardened products, digital power management products, broadband and hot plug power management products, and high-speed data converters for applications in DSL, home gateway, satellite, networking, cellular base station, and networking/switching equipment markets. The company markets its products through distributors and value added resellers to original equipment manufacturers, original design manufacturers, and contract manufacturers in China, the United States, South Korea, Taiwan, Japan, Germany, Singapore, and Mexico. Intersil Corporation was founded in 1999 and is headquartered in Milpitas, California.
Advisors' Opinion:- [By Jake L'Ecuyer]
Intersil (NASDAQ: ISIL) tumbled 4.81 percent to $10.92 after Evercore Partners downgraded the stock from Equal-Weight to Underweight.
Texas Industries (NYSE: TXI) was down, falling 4.36 percent to $65.78 after Longbow Research downgraded the stock from buy to neutral.
- [By Seth Jayson]
Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Intersil (Nasdaq: ISIL ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Intersil doing by this quick checkup? At first glance, pretty well. Trailing-12-month revenue decreased 18.7%, and inventory decreased 19.5%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue shrank 15.6%, and inventory shrank 19.5%. Over the sequential quarterly period, the trend looks OK but not great. Revenue dropped 4.2%, and inventory dropped 3.1%.
10 Best Tech Stocks To Watch For 2014: ServiceSource International Inc.(SREV)
ServiceSource International, Inc. manages the service contract renewals process of maintenance, support and subscription agreements for technology and technology-enabled healthcare, and life sciences companies. The company provides end-to-end management and optimization of the service contract renewals process, including data management, quoting, selling, and service revenue business intelligence. It offers an integrated solution that consists of Service Revenue Intelligence Platform, a data warehouse of transactional, analytical, and industry data that provides insight into the business; service sales teams working under its customers? brands; and Service Revenue Performance Suite, a suite of cloud applications. The company?s cloud applications include Analytics Cloud, which provides customers with dashboards to view and analyze service revenue performance; Service Sales Cloud that provides renewals analytics and pipeline management used by service sales teams; and Chan nel Sales Cloud, which offers channel partners and resellers with online access to their specific renewals opportunities and their performance. Its cloud applications also comprise eCommerce Cloud that provides self-service capabilities to end customers through a secure online portal; Installed Base Intelligence Cloud, which offers a single repository to analyze the data, to flag anomalies and missing data elements, and to identify cross-sell and up-sell opportunities; and Dynamic Quoting Cloud that provides an easy-to-use tool for sales representatives and channel partners to create and modify service renewal quotes. The company sells its solutions directly through sales representatives in North America, Latin America, Europe, the Middle East, Africa, the Asia Pacific, and Japan. ServiceSource International, Inc. was founded in 2002 and is headquartered in San Francisco, California with additional offices in Colorado, Tennessee, Ireland, the United Kingdom, Malaysia, and Si ngapore.
Advisors' Opinion:- [By Lee Jackson]
Service Source International Inc. (NASDAQ: SREV) is a small cap name with big possibilities. The company provides recurring revenue management contracts maintenance, support and subscription for technology and technology-enabled health care and life sciences companies. The consensus price objective for the stock is $14.
- [By Jake L'Ecuyer]
ServiceSource (NASDAQ: SREV) shares were also down, falling 32.48 percent to $4.22 as the company missed on earnings and caught a downgrade from CLSA from Buy to Underperform.
- [By Steve Symington]
What:�Shares of Servicesource International Inc (NASDAQ: SREV ) plunged nearly 33% Friday after the recurring-revenue-management company turned in disappointing first-quarter results.
- [By Evan Niu, CFA]
What: Shares of ServiceSource (NASDAQ: SREV ) have soared by as much as 24% today after the company reported first-quarter earnings.
So what: Revenue in the first quarter totaled $61.1 million, higher than the $60.4 million consensus estimate. The non-GAAP net loss of $1.5 million, or $0.02 per share, was also better than the $0.04-per-share loss that investors were expecting. The company inked four new Renew OnDemand subscription deals during the quarter.
No comments:
Post a Comment